Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
Cancer Res. 2011 Dec 1;71(23):7301-11. doi: 10.1158/0008-5472.CAN-11-2381. Epub 2011 Oct 6.
CD97, an adhesion-linked G-protein-coupled receptor (GPCR), is induced in multiple epithelial cancer lineages. We address here the signaling properties and the functional significance of CD97 expression in prostate cancer. Our findings show that CD97 signals through Gα12/13 to increase RHO-GTP levels. CD97 functioned to mediate invasion in prostate cancer cells, at least in part, by associating with lysophosphatidic acid receptor 1 (LPAR1), leading to enhanced LPA-dependent RHO and extracellular signal-regulated kinase activation. Consistent with its role in invasion, depletion of CD97 in PC3 cells resulted in decreased bone metastasis without affecting subcutaneous tumor growth. Furthermore, CD97 heterodimerized and functionally synergized with LPAR1, a GPCR implicated in cancer progression. We also found that CD97 and LPAR expression were significantly correlated in clinical prostate cancer specimens. Taken together, these findings support the investigation of CD97 as a potential therapeutic cancer target.
CD97 是一种黏附连接的 G 蛋白偶联受体 (GPCR),在多种上皮性癌细胞系中被诱导表达。我们在此探讨了 CD97 在前列腺癌中的表达的信号特性和功能意义。我们的研究结果表明,CD97 通过 Gα12/13 信号转导来增加 RHO-GTP 水平。CD97 通过与溶血磷脂酸受体 1 (LPAR1) 结合来介导前列腺癌细胞的侵袭,至少部分是通过这种方式,从而增强 LPA 依赖性 RHO 和细胞外信号调节激酶的激活。与它在侵袭中的作用一致,在 PC3 细胞中敲低 CD97 会导致骨转移减少,而不影响皮下肿瘤的生长。此外,CD97 与 LPAR1 异二聚化并协同作用,LPAR1 是一种与癌症进展有关的 GPCR。我们还发现 CD97 和 LPAR 在临床前列腺癌标本中的表达显著相关。综上所述,这些发现支持将 CD97 作为一种潜在的治疗性癌症靶点进行研究。